168 related articles for article (PubMed ID: 27117493)
1. Severe, reversible nelarabine-induced neuropathy and myelopathy.
Alberti P; Parma M; Pioltelli P; Pogliani EM; Terruzzi E; Stasia A; Doni E; Cecchetti C; Cavaletti G
J Peripher Nerv Syst; 2016 Sep; 21(3):154-6. PubMed ID: 27117493
[No Abstract] [Full Text] [Related]
2. Pediatric T-ALL complicated by irreversible nelarabine neurotoxicity.
Kanayama T; Imamura T; Nakagawa N; Osone S; Hosoi H
Pediatr Int; 2017 Jul; 59(7):843-845. PubMed ID: 28745456
[No Abstract] [Full Text] [Related]
3. MR imaging in nelarabine-induced myelopathy.
Dua SG; Jhaveri MD
J Clin Neurosci; 2016 Jul; 29():205-6. PubMed ID: 26899359
[TBL] [Abstract][Full Text] [Related]
4. Irreversible myelopathy associated with nelaribine in T-cell acute lymphoblastic leukemia.
Gollard RP; Selco S
J Clin Oncol; 2013 Jul; 31(19):e327-31. PubMed ID: 23715575
[No Abstract] [Full Text] [Related]
5. Nelarabine-associated reversible Guillain-Barré-like syndrome or myelopathy in an adult patient with primary refractory T-lymphoblastic lymphoma.
Lalayanni C; Baldoumi E; Papayiannopoulos S; Tziola K; Saloum R; Anagnostopoulos A
Curr Probl Cancer; 2017; 41(2):138-143. PubMed ID: 28169005
[TBL] [Abstract][Full Text] [Related]
6. Nelarabine-associated myelopathy in a patient with acute lymphoblastic leukaemia: Case report.
Amer-Salas N; González-Morcillo G; Rodríguez-Camacho JM; Cladera-Serra A
J Oncol Pharm Pract; 2021 Jan; 27(1):244-249. PubMed ID: 32517638
[TBL] [Abstract][Full Text] [Related]
7. Nelarabine neurotoxicity with concurrent intrathecal chemotherapy: Case report and review of literature.
Ngo D; Patel S; Kim EJ; Brar R; Koontz MZ
J Oncol Pharm Pract; 2015 Aug; 21(4):296-300. PubMed ID: 24664478
[TBL] [Abstract][Full Text] [Related]
8. Nelarabine-induced peripheral and central neurotoxicity: can sequential MRI brain imaging help to define its natural history?
Ewins K; Malone A; Phelan E; Webb D; McHugh JC; Smith O
Br J Haematol; 2017 Oct; 179(2):294-297. PubMed ID: 28961308
[TBL] [Abstract][Full Text] [Related]
9. Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient.
Papayannidis C; Iacobucci I; Abbenante MC; Curti A; Paolini S; Parisi S; Baccarani M; Martinelli G
Am J Hematol; 2010 Aug; 85(8):608. PubMed ID: 20658590
[No Abstract] [Full Text] [Related]
10. Coma associated with nelarabine in an elderly patient with T-cell acute lymphoblastic leukemia and severe chronic renal disease.
Nishijima TF; Shea TC; Wood WA; Voorhees PM; Jamieson K
Leuk Lymphoma; 2016; 57(4):957-60. PubMed ID: 26293208
[No Abstract] [Full Text] [Related]
11. Fatal neurological side-effects with necrosis of spinal cord following nelarabine treatment in a child with relapsed T-cell acute lymphoblastic leukemia.
Hartz B; Löbel U; Hagel C; Escherich G
Am J Hematol; 2013 Dec; 88(12):1096-7. PubMed ID: 23873785
[No Abstract] [Full Text] [Related]
12. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Dunsmore KP; Devidas M; Linda SB; Borowitz MJ; Winick N; Hunger SP; Carroll WL; Camitta BM
J Clin Oncol; 2012 Aug; 30(22):2753-9. PubMed ID: 22734022
[TBL] [Abstract][Full Text] [Related]
13. Management of Nelarabine induced neurotoxicity in a child with T-cell acute lymphoblastic lymphoma.
Karthik U; Motwani J
J Oncol Pharm Pract; 2024 Apr; 30(3):594-596. PubMed ID: 38105625
[TBL] [Abstract][Full Text] [Related]
14. Nelarabine-induced myelopathy in patients undergoing allogeneic hematopoietic cell transplantation: a report of three cases.
Fukuta T; Tanaka T; Hashimoto T; Isahaya K; Kubo Y; Yamano Y; Satomi K; Hiraoka N; Shirakawa N; Arakawa A; Ogawa C; Nishimura N; Aoki J; Ito A; Inamoto Y; Kim SW; Fukuda T
Int J Hematol; 2023 Jun; 117(6):933-940. PubMed ID: 36705847
[TBL] [Abstract][Full Text] [Related]
15. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
Candoni A; Lazzarotto D; Petruzzellis G
Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913
[TBL] [Abstract][Full Text] [Related]
16. Imaging Findings in Children Presenting with CNS Nelarabine Toxicity.
Serrallach BL; Schafer ES; Kralik SK; Tran BH; Huisman TAGM; Wright JN; Morgan LA; Desai NK
AJNR Am J Neuroradiol; 2022 Dec; 43(12):1802-1809. PubMed ID: 36328408
[TBL] [Abstract][Full Text] [Related]
17. [Severe liver injury following nelarabine chemotherapy for T-cell lymphoblastic lymphoma].
Iino M
Rinsho Ketsueki; 2009 Jan; 50(1):49-51. PubMed ID: 19225230
[TBL] [Abstract][Full Text] [Related]
18. Central nervous system neurotoxicity associated with nelarabine in T-cell acute lymphoblastic leukemia.
Pehlivan UA; Gürkan E; Açar İH; Bıçakcı YK
J Oncol Pharm Pract; 2023 Jan; 29(1):246-251. PubMed ID: 35593112
[TBL] [Abstract][Full Text] [Related]
19. Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy.
Kuhlen M; Bleckmann K; Möricke A; Schrappe M; Vieth S; Escherich G; Bronsema A; Vonalt A; Queudeville M; Zwaan CM; Ebinger M; Debatin KM; Klingebiel T; Koscielniak E; Rossig C; Burkhardt B; Kolb R; Eckert C; Borkhardt A; von Stackelberg A; Chen-Santel C
Br J Haematol; 2017 Oct; 179(2):272-283. PubMed ID: 28771662
[TBL] [Abstract][Full Text] [Related]
20. Neurotoxicity of cancer chemotherapy.
Dropcho EJ
Semin Neurol; 2010 Jul; 30(3):273-86. PubMed ID: 20577934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]